Study #2021-1108
Phase II study of pirtobrutinib with venetoclax in relapsed-refractory mcl (mantle cell lymphoma) patients
MD Anderson Study Status
Enrolling
Treatment Agent
Pirtobrutinib, Venetoclax
Description
To learn if the combination of pirtobrutinib (also called LOXO-305) and venetoclax can help to control mantle cell lymphoma (MCL) that is relapsed (has come back) or refractory (has not responded to therapy).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Mantle Cell Lymphoma, Non Hodgkin Lymphoma, Hematologic Malignancy
Study phase:
Phase II
Physician name:
Preetesh Jain
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-844-513-2253
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.